Lakewood-based KRTL Holding Group Inc. (OTC: KRTL) announced that its subsidiary, KRTL Biotech Inc., has successfully registered Industria Químico Farmaceutica SIGMA CORP. S.R.L. (SIGMACORP) with the U.S. Food and Drug Administration (FDA) as a U.S. pharmaceutical manufacturer. As the U.S. Registered Agent for SIGMACORP, KRTL Biotech is facilitating international pharmaceutical integration and diversifying the U.S. healthcare supply chain.
The FDA registration marks a significant achievement in KRTL Biotech’s efforts to connect international pharmaceutical innovation with U.S. regulatory standards. This development allows for the potential introduction of cost-efficient, high-quality pharmaceutical products into the U.S. market, enhancing KRTL’s global partnership objectives.
Key implications of this registration include:
- Expanding market opportunities: With SIGMACORP now approved to manufacture for the U.S., the partnership supports the introduction of affordable and reliable pharmaceutical products.
- Enhancing competitive edge: This registration highlights KRTL Biotech’s leadership in international pharmaceutical collaboration, enabling the development of strategic alliances and revenue opportunities.
- Supporting U.S. healthcare resilience: This initiative broadens the pharmaceutical supply chain, contributing to sustainability and innovation.
This milestone also signifies progress in U.S.-Bolivia healthcare relations. KRTL Biotech’s facilitation of SIGMACORP’s entry into the U.S. market demonstrates a commitment to advancing global healthcare solutions.
“This accomplishment reflects our dedication to creating meaningful global partnerships that address critical healthcare needs,” said Cesar Herrera, CEO of KRTL Holding Group Inc. “Facilitating SIGMACORP’s FDA registration exemplifies our vision of leveraging international collaboration to deliver innovative and cost-effective solutions to the U.S. market.”
